Zhou et al. (2019) reported that inhibitors of Hsp90α can be used for treating HCC with fewer toxic adverse effects. Hu, Yang & Sang (2020) and Chen et al. (2021) included HSP family A (Hsp70) member four (HSPA4) in a risk score model that consisted of several differentially expressed immune genes to predict the prognosis for HCC. The gene discussed is HSPA4; the disease is hepatocellular carcinoma.